Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis

  • Pose, Elisa|||0000-0002-0224-7686
  • Solà, Elsa|||0000-0001-6897-2760
  • Lozano, Juan José
  • Juanola, Adrià|||0000-0003-4832-5130
  • Sidorova, Julia
  • Zaccherini, Giacomo|||0000-0002-3219-6963
  • de Wit, Koos|||0000-0001-8472-8549
  • Uschner, Frank
  • Tonon, Marta
  • Kazankov, Konstantin
  • Jiménez, Cesar|||0000-0003-2455-2048
  • Campion, Daniela
  • Napoleone, Laura
  • Ma, Ann T.|||0000-0002-9059-111X
  • Carol, Marta
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Alessandria, Carlo|||0000-0001-5468-694X
  • Beuers, Ulrich
  • Caraceni, Paolo|||0000-0002-1439-056X
  • Francoz, Claire|||0000-0001-7391-8507
  • Durand, François
  • Mookerjee, Rajeshwar P.
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Vargas Blasco, Víctor|||0000-0002-7190-6948
  • Piano, Salvatore|||0000-0002-9356-5830
  • Watson, Hugh|||0000-0002-6931-3158
  • Abraldes, Juan G.|||0000-0003-3421-937X
  • Kamath, P.S.|||0000-0002-7888-1165
  • Davis, Mark M.
  • Ginès, Pere|||0000-0003-4657-4504
Patients with decompensated cirrhosis, particularly those with acute-on-chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma metabolites of patients with decompensated cirrhosis, specifically on compounds characteristic of the ACLF plasma metabolomic profile. Two cohorts of patients were investigated. The first was a descriptive cohort of patients with decompensated cirrhosis (n = 42), with and without ACLF. The second was an intervention cohort from the LIVERHOPE-SAFETY randomized, double-blind, placebo-controlled trial treated with simvastatin 20 mg/day plus rifaximin 1,200 mg/day (n = 12) or matching placebo (n = 13) for 3 months. Plasma samples were analyzed using ultrahigh performance liquid chromatography-tandem mass spectroscopy for plasma metabolomics characterization. ACLF was characterized by intense proteolysis and lipid alterations, specifically in pathways associated with inflammation and mitochondrial dysfunction, such as the tryptophan-kynurenine and carnitine beta-oxidation pathways. An ACLF-specific signature was identified. Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabolites in comparison to treatment with placebo. A remarkable reduction in levels of metabolites from the tryptophan-kynurenine and carnitine pathways was found. Notably, 18 of the 32 metabolites of the ACLF signature were affected by the treatment. Conclusion: Treatment with simvastatin and rifaximin modulates some of the pathways that appear to be key in ACLF development. This study unveils some of the mechanisms involved in the effects of treatment with simvastatin and rifaximin in decompensated cirrhosis and sets the stage for the use of metabolomics to investigate new targeted therapies in cirrhosis to prevent ACLF development.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis

  • Solé, Cristina
  • Guilly, Susie
  • Da Silva, Kevin
  • Llopis, Marta
  • Le-Chatelier, Emmanuelle
  • Huelin Álvarez, Patricia
  • Carol, Marta
  • Moreira, Rebeca
  • Fabrellas, Núria
  • De Prada, Gloria
  • Napoleone, Laura
  • Graupera, Isabel
  • Pose, Elisa
  • Juanola, Adrià
  • Borruel, Natalia
  • Berland, Magali
  • Toapanta, David
  • Casellas, Francesc
  • Guarner, Francisco
  • Doré, Jöel
  • Solà, Elsa
  • Ehrlich, Stanislav Dusko
  • Ginès, Pere
Cirrhosis is associated with changes in gut microbiome composition. Although acute-on-chronic liver failure (ACLF) is the most severe clinical stage of cirrhosis, there is lack of information about gut microbiome alterations in ACLF using quantitative metagenomics. We investigated the gut microbiome in patients with cirrhosis encompassing the whole spectrum of disease (compensated, acutely decompensated without ACLF, and ACLF). A group of healthy subjects was used as control subjects., Stool samples were collected prospectively in 182 patients with cirrhosis. DNA library construction and sequencing were performed using the Ion Proton Sequencer (ThermoFisher Scientific, Waltham, MA). Microbial genes were grouped into clusters, denoted as metagenomic species., Cirrhosis was associated with a remarkable reduction in gene and metagenomic species richness compared with healthy subjects. This loss of richness correlated with disease stages and was particularly marked in patients with ACLF and persisted after adjustment for antibiotic therapy. ACLF was associated with a significant increase of Enterococcus and Peptostreptococcus sp and a reduction of some autochthonous bacteria. Gut microbiome alterations correlated with model for end-stage liver disease and Child-Pugh scores and organ failure and was associated with some complications, particularly hepatic encephalopathy and infections. Interestingly, gut microbiome predicted 3-month survival with good stable predictors. Functional analysis showed that patients with cirrhosis had enriched pathways related to ethanol production, γ-aminobutyric acid metabolism, and endotoxin biosynthesis, among others., Cirrhosis is characterized by marked alterations in gut microbiome that parallel disease stages with maximal changes in ACLF. Altered gut microbiome was associated with complications of cirrhosis and survival. Gut microbiome may contribute to disease progression and poor prognosis. These results should be confirmed in future studies., Sponsored in part by the Instituto de Salud Carlos III through the Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016, project reference PI 12/00330 and PI 16/00043. This grant was co-funded by the European Regional Development Fund (FEDER). This study has been supported in part by an EU Horizon 20/20 Programme (Grant/Award Number H2020-SC1-2016-RTD), LIVERHOPE (Grant/Award Number 731875), and in part by Metagenopolis Grant ANR-11-DPBS-0001 (to Stanislav Dusko Ehrlich). Pere Ginès is a recipient of an ICREA Academia Award.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis

  • Solé Padullés, Cristina
  • Guilly, Susie
  • Da Silva, Kevin
  • Llopis, Marta
  • Le-Chatelier, Emmanuelle
  • Huelin, Patricia
  • Carol, Marta
  • Moreira, Rebeca
  • Fabrellas i Padrès, Núria
  • de la Prada, Gloria
  • Napoleone, Laura
  • Graupera, Isabel
  • Pose Méndez, Elisa
  • Juanola Mayos, Adrià
  • Borruel, Natalia
  • Berland, Magali
  • Toapanta, David
  • Casellas, Francesc
  • Guarner, Francisco
  • Doré, Jöel
  • Solà, Elsa
  • Ehrlich, Stanislav Dusko
  • Ginès i Gibert, Pere
Background and Aims: Cirrhosis is associated with changes in gut microbiome composition. Although acute-on-chronic liver failure (ACLF) is the most severe clinical stage of cirrhosis, there is lack of information about gut microbiome alterations in ACLF using quantitative metagenomics. We investigated the gut microbiome in patients with cirrhosis encompassing the whole spectrum of disease (compensated, acutely decompensated without ACLF, and ACLF). A group of healthy subjects was used as control subjects. Methods: Stool samples were collected prospectively in 182 patients with cirrhosis. DNA library construction and sequencing were performed using the Ion Proton Sequencer (ThermoFisher Scientific, Waltham, MA). Microbial genes were grouped into clusters, denoted as metagenomic species. Results: Cirrhosis was associated with a remarkable reduction in gene and metagenomic species richness compared with healthy subjects. This loss of richness correlated with disease stages and was particularly marked in patients with ACLF and persisted after adjustment for antibiotic therapy. ACLF was associated with a significant increase of Enterococcus and Peptostreptococcus sp and a reduction of some autochthonous bacteria. Gut microbiome alterations correlated with model for end-stage liver disease and Child-Pugh scores and organ failure and was associated with some complications, particularly hepatic encephalopathy and infections. Interestingly, gut microbiome predicted 3-month survival with good stable predictors. Functional analysis showed that patients with cirrhosis had enriched pathways related to ethanol production, γ-aminobutyric acid metabolism, and endotoxin biosynthesis, among others. Conclusions: Cirrhosis is characterized by marked alterations in gut microbiome that parallel disease stages with maximal changes in ACLF. Altered gut microbiome was associated with complications of cirrhosis and survival. Gut microbiome may contribute to disease progression and poor prognosis. These results should be confirmed in future studies.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The role of macrophage-inducible C-type lectin in different stages of chronic liver disease

  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Ortiz, Cristina
  • Torres, Sandra
  • Brol, Max J.
  • Tyc, Olaf
  • Gu, Wenyi
  • Grimm, Christian
  • Zeuzem, Stefan
  • Plamper, Andreas
  • Pfeifer, Philipp
  • Zimmer, Sebastian
  • Welsch, Christoph
  • Schaefer, Liliana
  • Rheinwalt, Karl P.
  • Clària i Enrich, Joan
  • Arroyo, Vicente
  • Trebicka, Jonel
  • Klein, Sabine
The macrophage-inducible C-type lectin (mincle) is part of the innate immune system and acts as a pattern recognition receptor for pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPs). Ligand binding induces mincle activation which consequently interacts with the signaling adapter Fc receptor, SYK, and NF-kappa-B. There is also evidence that mincle expressed on macrophages promotes intestinal barrier integrity. However, little is known about the role of mincle in hepatic fibrosis, especially in more advanced disease stages. Mincle expression was measured in human liver samples from cirrhotic patients and donors collected at liver transplantation and in patients undergoing bariatric surgery. Human results were confirmed in rodent models of cirrhosis and acute-on-chronic liver failure (ACLF). In these models, the role of mincle was investigated in liver samples as well as in peripheral blood monocytes (PBMC), tissues from the kidney, spleen, small intestine, and heart. Additionally, mincle activation was stimulated in experimental non-alcoholic steatohepatitis (NASH) by treatment with mincle agonist trehalose-6,6-dibehenate (TDB). In human NASH, mincle is upregulated with increased collagen production. In ApoE deficient mice fed high-fat western diet (NASH model), mincle activation significantly increases hepatic collagen production. In human cirrhosis, mincle expression is also significantly upregulated. Furthermore, mincle expression is associated with the stage of chronic liver disease. This could be confirmed in rat models of cirrhosis and ACLF. ACLF was induced by LPS injection in cirrhotic rats. While mincle expression and downstream signaling via FC receptor gamma, SYK, and NF-kappa-B are upregulated in the liver, they are downregulated in PBMCs of these rats. Although mincle expressed on macrophages might be beneficial for intestinal barrier integrity, it seems to contribute to inflammation and fibrosis once the intestinal barrier becomes leaky in advanced stages of chronic liver disease.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project

  • Fabrellas i Padrès, Núria
  • Carol, Marta
  • Palacio, Ester
  • Aban, Marites
  • Lanzillotti, Tommaso
  • Nicolao, Gea
  • Chiappa, Maria Teresa
  • Esnault, Vanessa
  • Graf Dirmeier, Sabine
  • Helder, Jeltje
  • Gossard, Andrea
  • López, Mireia
  • Cervera, Marta
  • Dols, Lacey L.
  • LiverHope consortium investigators
  • Ginès i Gibert, Pere
Cirrhosis is a complex disease that is associated with disturbances in different organs besides the liver, including kidneys, heart, arterial circulation, lungs, gut, and brain. As a consequence, patients develop a number of complications that result in frequent hospital admissions and high morbidity and mortality. Patients with cirrhosis require constant and rigorous monitoring both in and outside the hospital. In this context, the role of nurses in the care of patients with cirrhosis has not been sufficiently emphasized and there is very limited information about nursing care of patients with cirrhosis compared with other chronic diseases. The current article provides a review of nursing care for the different complications of patients with cirrhosis. Nurses with specific knowledge on liver diseases should be incorporated into multidisciplinary teams managing patients with cirrhosis, both inpatient and outpatient. Conclusion: Nurses play an important role in the management and prevention of complications of the disease and improvement in patients' quality of life and bridge the gap between clinicians and families, between primary care and hospital care, and provide medical education to patients and caregivers.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?

  • Schwarzkopf, Katharina Maria
  • Eberle, Larissa
  • Uschner, Frank Erhard
  • Klein, Sabine
  • Schierwagen, Robert
  • Muecke, Marcus M.
  • Schaefer, Liliana
  • Clària i Enrich, Joan
  • Zeuzem, Stefan
  • Hintermann, Edith
  • Christen, Urs
  • Lange, Christian Markus
  • Trebicka, Jonel
  • Welsch, Christoph
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium

  • Solà, Elsa
  • Pose Méndez, Elisa
  • Campion, Daniela
  • Piano, Salvatore
  • Roux, Olivier
  • Simón Talero, Macarena
  • Uschner, Frank Erhard
  • de Wit, Koos
  • Zaccherini, Giacomo
  • Alessandria, Carlo
  • Beuers, Ulrich
  • Caraceni, Paolo
  • Francoz, Claire
  • Mookerjee, Rajeshwar P.
  • Trebicka, Jonel
  • Vargas, Víctor
  • Serra, Miquel
  • Torres, Ferran
  • Montagnese, Sara
  • Krag, Aleksander
  • Hernaez, Rubén
  • Korenjak, Marko
  • Watson, Hugh
  • Abraldes, Juan G.
  • Kamath, Patrick S.
  • Ginès i Gibert, Pere
  • LiverHope consortium investigators
Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.

  • Solé Padullés, Cristina
  • Solà, Elsa
  • Huelin, Patricia
  • Carol, Marta
  • Moreira, Rebeca
  • Cereijo, Unai
  • Mas, José Manuel
  • Graupera, Isabel
  • Pose Méndez, Elisa
  • Napoleone, Laura
  • de la Prada, Gloria
  • Juanola Mayos, Adrià
  • Fabrellas i Padrès, Núria
  • Torres, Ferran
  • Morales Ruiz, Manuel
  • Farrés, Judith
  • Jiménez Povedano, Wladimiro
  • Ginès i Gibert, Pere
Background: Several lines of evidence indicate that decompensated cirrhosis is characterized by the presence of systemic inflammation. Hepatorenal syndrome (HRS-AKI) is a unique type of renal failure that occurs at late stages of cirrhosis. However, confirmation of the presence and significance of such inflammatory response in HRS-AKI is lacking. Aim and methods: To characterize the systemic inflammatory response, as estimated by measuring a large number of cytokines, in 161 patients hospitalized for an acute decompensation of cirrhosis: 44 patients without acute kidney injury (AKI), 63 patients with hypovolaemia-induced AKI and 58 patients with HRS-AKI. Results: HRS-AKI was characterized by an altered cytokine profile compared to the other two groups, particularly IL-6, IL-8, TNF-α, VCAM-1, fractalkine and MIP-1α. The inflammatory response was not related to presence of bacterial infection, concomitant acute-on-chronic liver failure or severity of renal dysfunction. Patients who responded to terlipressin and albumin had only a decrease in TNF-α and RANTES after treatment without changes in other cytokines. Interestingly, patients with persistent HRS-AKI had higher levels of IP-10 and VCAM-1 compared to those with resolution of HRS-AKI. VCAM-1 was also an independent predictor of 3-month mortality. A systems biology analysis approach showed that the inflammatory status of HRS-AKI was similar to that of chronic nonhepatic inflammatory conditions, such as lupus erythematosus or inflammatory bowel disease. Conclusion: Hepatorenal syndrome is characterized by a marked systemic inflammatory state, reminiscent of that of nonhepatic inflammatory diseases, that correlates with patient outcomes.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Statins: Old drugs as new therapy for liver diseases?

  • Pose Méndez, Elisa
  • Trebicka, Jonel
  • Mookerjee, Rajeshwar P.
  • Angeli, Paolo
  • Ginès i Gibert, Pere
In addition to lowering cholesterol levels, statins have pleiotropic effects, particularly anti-inflammatory, antiangiogenic, and antifibrotic, that may be beneficial in some chronic inflammatory conditions. Statins have only recently been investigated as a potential treatment option in chronic liver diseases because of concerns related to their safety in patients with impaired liver function. A number of experimental studies in animal models of liver diseases have shown that statins decrease hepatic inflammation, fibrogenesis and portal pressure. In addition, retrospective cohort studies in large populations of patients with cirrhosis and pre-cirrhotic conditions have shown that treatment with statins, with the purpose of decreasing high cholesterol levels, was associated with a reduced risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and death. These beneficial effects persisted after adjustment for disease severity and other potential confounders. Finally, a few randomised controlled trials have shown that treatment with simvastatin decreases portal pressure (two studies) and mortality (one study). Statin treatment was generally well tolerated but a few patients developed severe side effects, particularly rhabdomyolysis. Despite these promising beneficial effects, further randomised controlled trials in large series of patients with hard clinical endpoints should be performed before statins can be recommended for use in clinical practice.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

  • Torres, Sandra
  • Ortiz, Cristina
  • Bachtler, Nadine
  • Gu, Wenyi
  • Grünewald, Leon D.
  • Kraus, Nico
  • Schierwagen, Robert
  • Hieber, Christoph
  • Meier, Caroline
  • Tyc, Olaf
  • Brol, Maximilian Joseph
  • Uschner, Frank Erhard
  • Nijmeijer, Bart
  • Welsch, Christoph
  • Berres, Marie-Luise
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Trautwein, Christian
  • Vogl, Thomas J.
  • Zeuzem, Stefan
  • Trebicka, Jonel
  • Klein, Sabine
anus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be effective in liver fibrosis. Here, we investigated the antifibrotic role of the JAK2 inhibitor pacritinib on activated hepatic stellate cells (HSCs) in vitro and in two animal models of liver fibrosis in vivo., Jonel Trebicka is supported by the German Research Foundation project ID 403224013–SFB 1382 (A09); by the German Federal Ministry of Education and Research (BMBF) for the DEEP‐HCC project; by the Hessian Ministry of Higher Education, Research, and the Arts (HMWK) for the ENABLE cluster project; and by Eurostars (Grant ID 12350). The MICROB‐PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 964590) projects have received funding from the European Union's Horizon 2020 research and innovation program. The manuscript reflects only the authors' views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Palmitoylcarnitine impairs immunity in decompensated cirrhosis

  • Wei Zhang, Ingrid
  • Sánchez-Rodríguez, María Belén
  • López-Vicario, Cristina
  • Casulleras, Mireia
  • Duran-Güell, Marta
  • Flores-Costa, Roger
  • Aguilar, Ferran
  • Rothe, Michael
  • Segalés, Paula
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Trebicka, Jonel
  • Arroyo, Vicente
  • Clària, Joan
In patients with cirrhosis, acute decompensation (AD) correlates with a hyperinflammatory state driven by mitochondrial dysfunction, which is a significant factor in the progression toward acute-on-chronic liver failure (ACLF). Elevated circulating levels of acylcarnitine, indicative of mitochondrial dysfunction, are predictors of mortality in ACLF patients. Our hypothesis posits that acylcarnitines not only act as biomarkers, but also actively exert detrimental effects on circulating immune cells., Supported by the Plan Nacional de I+D funded by the Agencia Estatal de Investigación (grants PID2019-105240RB-I00 and PID2022-138970OB-I00 [to JC] and PID2019-111669RB-100 and PID2020-115055RB-I00 [to JCF-C]). JC laboratory is a Consolidated Research Group recognised by the Generalitat de Catalunya (2021 SGR 01323) and receives funds from EF CLIF and European Union’s Horizon 2020 research and innovation programme (MICROB-PREDICT [project ID 825694], DECISION [project ID 847949]). JCF-C receives funds from the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH, the Project 201916/31 by Fundació Marató TV3 and the European Horizon´s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. JT is supported by the German Research Foundation project ID 403224013 – SFB 1382 (A09), by the German Federal Ministry of Education and Research for the DEEP-HCC project and by the Hessian Ministry of Higher Education, Research, the Arts for the ENABLE and ACLF-I cluster projects and the European Union’s Horizon 2020 research and innovation program for MICROB-PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 964590) projects. IWZ was supported by the Sheila Sherlock Post Graduate Programme of the European Association for the Study of the Liver., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis

  • Torres, Sandra
  • Brol, Maximilian J.
  • Magdaleno, Fernando
  • Schierwagen, Robert
  • Uschner, Frank E.
  • Klein, Sabine
  • Ortiz, Cristina
  • Tyc, Olaf
  • Bachtler, Nadine
  • Stunden, James
  • Bertheloot, Damien
  • Kitanovic, Ana
  • Sanchez, Brian
  • Schrum, Jacob
  • Roush, William R.
  • Franchi, Luigi
  • Byth, Kate
  • Latz, Eicke
  • Trebicka, Jonel
Background and Aims: Activation of the inflammasome NLRP3 (NOD-, LRR- and pyrin domain containing 3) contributes to the development of non-alcoholic fatty liver disease (NAFLD) and progression to non-alcoholic steatohepatitis (NASH). Therefore, this study explored the therapeutic effects of a novel and selective NLRP3 antagonist in a murine dietary model of NASH. Methods: Groups of 12-week-old ApoE -/- mice were fed ad lib for 7 weeks with a methionine/choline deficient (MCD) and western diet (WD). After 3 weeks of diet-induced injury, mice were injected i. p. with the NLRP3 antagonist IFM-514 (100 mg/kg body weight) or vehicle (0.5% carmellose) every day, 5 days/week for a further 4 weeks. Several markers of inflammation, fibrosis and steatosis were evaluated. Whole transcriptome sequencing and panel RNA expression analysis (NanoString) were performed. Results: IFM-514 inhibited IL-1β production in mice challenged with 20 mg/kg lipopolysaccharide, and in mouse and human inflammatory cells in vitro. IFM-514 inhibited hepatic inflammation in the in vivo non-alcoholic steatohepatitis model assessed by H&E staining and in the hepatic gene expression of inflammasome-related proinflammatory cytokines. This effect was associated with significant reduction in caspase-1 activation. Similarly, IFM-514 was efficacious in vivo in MDC-fed ApoE -/- mice, markedly reducing portal pressure, Sirius red staining and 4-hydroxyproline content compared to vehicle-treated mice. Moreover, IFM-514 significantly reduced hepatic steatosis in MCD-fed ApoE -/- mice, as evidenced by NAFLD scores, oil red O staining, hepatic triglycerides and gene expression. In WD treated animals, similar trends in inflammation and fibrosis were observed, although not sufficient IFM-514 levels were reached. Conclusion: Overall, IFM-514 reduced liver inflammation and fibrosis, with mild effects on liver steatosis in experimental murine NASH. Blocking of NLRP3 may be an attractive therapeutic approach for NASH patients., This study received funding from the Deutsche Forschungsgemeinschaft (SFB TRR57 and CRC1382), European Union's Horizon 2020 Research and Innovation Programme (Galaxy, No. 668031, MICROB-PREDICT, No. 825694, and DECISION No. 84794), Societal Challenges-Health, Demographic Change, and Well-Being (No. 731875), Cellex Foundation (PREDICT), LIVERHOPE (No. 731875), Enable (funded by Hessian Ministry of Higher Education, Research, Science and the Arts) and deep-HCC (German Federal Ministry of Education and Research). These funders had no involvement in the design of the study., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium

  • Solà, Elsa
  • Pose Méndez, Elisa
  • Campion, Daniela
  • Piano, Salvatore
  • Roux, Olivier
  • Simón Talero, Macarena
  • Uschner, Frank Erhard
  • de Wit, Koos
  • Zaccherini, Giacomo
  • Alessandria, Carlo
  • Beuers, Ulrich
  • Caraceni, Paolo
  • Francoz, Claire
  • Mookerjee, Rajeshwar P.
  • Trebicka, Jonel
  • Vargas, Víctor
  • Serra, Miquel
  • Torres, Ferran
  • Montagnese, Sara
  • Krag, Aleksander
  • Hernaez, Rubén
  • Korenjak, Marko
  • Watson, Hugh
  • Abraldes, Juan G.
  • Kamath, Patrick S.
  • Ginès i Gibert, Pere
  • LiverHope consortium investigators
Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project

  • Fabrellas i Padrès, Núria
  • Carol, Marta
  • Palacio, Ester
  • Aban, Marites
  • Lanzillotti, Tommaso
  • Nicolao, Gea
  • Chiappa, Maria Teresa
  • Esnault, Vanessa
  • Graf Dirmeier, Sabine
  • Helder, Jeltje
  • Gossard, Andrea
  • López, Mireia
  • Cervera, Marta
  • Dols, Lacey L.
  • LiverHope consortium investigators
  • Ginès i Gibert, Pere
Cirrhosis is a complex disease that is associated with disturbances in different organs besides the liver, including kidneys, heart, arterial circulation, lungs, gut, and brain. As a consequence, patients develop a number of complications that result in frequent hospital admissions and high morbidity and mortality. Patients with cirrhosis require constant and rigorous monitoring both in and outside the hospital. In this context, the role of nurses in the care of patients with cirrhosis has not been sufficiently emphasized and there is very limited information about nursing care of patients with cirrhosis compared with other chronic diseases. The current article provides a review of nursing care for the different complications of patients with cirrhosis. Nurses with specific knowledge on liver diseases should be incorporated into multidisciplinary teams managing patients with cirrhosis, both inpatient and outpatient. Conclusion: Nurses play an important role in the management and prevention of complications of the disease and improvement in patients' quality of life and bridge the gap between clinicians and families, between primary care and hospital care, and provide medical education to patients and caregivers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis

  • Solé Padullés, Cristina
  • Guilly, Susie
  • Da Silva, Kevin
  • Llopis, Marta
  • Le-Chatelier, Emmanuelle
  • Huelin, Patricia
  • Carol, Marta
  • Moreira, Rebeca
  • Fabrellas i Padrès, Núria
  • de la Prada, Gloria
  • Napoleone, Laura
  • Graupera, Isabel
  • Pose Méndez, Elisa
  • Juanola Mayos, Adrià
  • Borruel, Natalia
  • Berland, Magali
  • Toapanta, David
  • Casellas, Francesc
  • Guarner, Francisco
  • Doré, Jöel
  • Solà, Elsa
  • Ehrlich, Stanislav Dusko
  • Ginès i Gibert, Pere
Background and Aims: Cirrhosis is associated with changes in gut microbiome composition. Although acute-on-chronic liver failure (ACLF) is the most severe clinical stage of cirrhosis, there is lack of information about gut microbiome alterations in ACLF using quantitative metagenomics. We investigated the gut microbiome in patients with cirrhosis encompassing the whole spectrum of disease (compensated, acutely decompensated without ACLF, and ACLF). A group of healthy subjects was used as control subjects. Methods: Stool samples were collected prospectively in 182 patients with cirrhosis. DNA library construction and sequencing were performed using the Ion Proton Sequencer (ThermoFisher Scientific, Waltham, MA). Microbial genes were grouped into clusters, denoted as metagenomic species. Results: Cirrhosis was associated with a remarkable reduction in gene and metagenomic species richness compared with healthy subjects. This loss of richness correlated with disease stages and was particularly marked in patients with ACLF and persisted after adjustment for antibiotic therapy. ACLF was associated with a significant increase of Enterococcus and Peptostreptococcus sp and a reduction of some autochthonous bacteria. Gut microbiome alterations correlated with model for end-stage liver disease and Child-Pugh scores and organ failure and was associated with some complications, particularly hepatic encephalopathy and infections. Interestingly, gut microbiome predicted 3-month survival with good stable predictors. Functional analysis showed that patients with cirrhosis had enriched pathways related to ethanol production, γ-aminobutyric acid metabolism, and endotoxin biosynthesis, among others. Conclusions: Cirrhosis is characterized by marked alterations in gut microbiome that parallel disease stages with maximal changes in ACLF. Altered gut microbiome was associated with complications of cirrhosis and survival. Gut microbiome may contribute to disease progression and poor prognosis. These results should be confirmed in future studies.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Statins: Old drugs as new therapy for liver diseases?

  • Pose Méndez, Elisa
  • Trebicka, Jonel
  • Mookerjee, Rajeshwar P.
  • Angeli, Paolo
  • Ginès i Gibert, Pere
In addition to lowering cholesterol levels, statins have pleiotropic effects, particularly anti-inflammatory, antiangiogenic, and antifibrotic, that may be beneficial in some chronic inflammatory conditions. Statins have only recently been investigated as a potential treatment option in chronic liver diseases because of concerns related to their safety in patients with impaired liver function. A number of experimental studies in animal models of liver diseases have shown that statins decrease hepatic inflammation, fibrogenesis and portal pressure. In addition, retrospective cohort studies in large populations of patients with cirrhosis and pre-cirrhotic conditions have shown that treatment with statins, with the purpose of decreasing high cholesterol levels, was associated with a reduced risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and death. These beneficial effects persisted after adjustment for disease severity and other potential confounders. Finally, a few randomised controlled trials have shown that treatment with simvastatin decreases portal pressure (two studies) and mortality (one study). Statin treatment was generally well tolerated but a few patients developed severe side effects, particularly rhabdomyolysis. Despite these promising beneficial effects, further randomised controlled trials in large series of patients with hard clinical endpoints should be performed before statins can be recommended for use in clinical practice.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.

  • Solé Padullés, Cristina
  • Solà, Elsa
  • Huelin, Patricia
  • Carol, Marta
  • Moreira, Rebeca
  • Cereijo, Unai
  • Mas, José Manuel
  • Graupera, Isabel
  • Pose Méndez, Elisa
  • Napoleone, Laura
  • de la Prada, Gloria
  • Juanola Mayos, Adrià
  • Fabrellas i Padrès, Núria
  • Torres, Ferran
  • Morales Ruiz, Manuel
  • Farrés, Judith
  • Jiménez Povedano, Wladimiro
  • Ginès i Gibert, Pere
Background: Several lines of evidence indicate that decompensated cirrhosis is characterized by the presence of systemic inflammation. Hepatorenal syndrome (HRS-AKI) is a unique type of renal failure that occurs at late stages of cirrhosis. However, confirmation of the presence and significance of such inflammatory response in HRS-AKI is lacking. Aim and methods: To characterize the systemic inflammatory response, as estimated by measuring a large number of cytokines, in 161 patients hospitalized for an acute decompensation of cirrhosis: 44 patients without acute kidney injury (AKI), 63 patients with hypovolaemia-induced AKI and 58 patients with HRS-AKI. Results: HRS-AKI was characterized by an altered cytokine profile compared to the other two groups, particularly IL-6, IL-8, TNF-α, VCAM-1, fractalkine and MIP-1α. The inflammatory response was not related to presence of bacterial infection, concomitant acute-on-chronic liver failure or severity of renal dysfunction. Patients who responded to terlipressin and albumin had only a decrease in TNF-α and RANTES after treatment without changes in other cytokines. Interestingly, patients with persistent HRS-AKI had higher levels of IP-10 and VCAM-1 compared to those with resolution of HRS-AKI. VCAM-1 was also an independent predictor of 3-month mortality. A systems biology analysis approach showed that the inflammatory status of HRS-AKI was similar to that of chronic nonhepatic inflammatory conditions, such as lupus erythematosus or inflammatory bowel disease. Conclusion: Hepatorenal syndrome is characterized by a marked systemic inflammatory state, reminiscent of that of nonhepatic inflammatory diseases, that correlates with patient outcomes.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?

  • Schwarzkopf, Katharina Maria
  • Eberle, Larissa
  • Uschner, Frank Erhard
  • Klein, Sabine
  • Schierwagen, Robert
  • Muecke, Marcus M.
  • Schaefer, Liliana
  • Clària i Enrich, Joan
  • Zeuzem, Stefan
  • Hintermann, Edith
  • Christen, Urs
  • Lange, Christian Markus
  • Trebicka, Jonel
  • Welsch, Christoph
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis

  • Solé, Cristina
  • Guilly, Susie
  • Da Silva, Kevin
  • Llopis, Marta
  • Le-Chatelier, Emmanuelle
  • Huelin Álvarez, Patricia
  • Carol, Marta
  • Moreira, Rebeca
  • Fabrellas, Núria
  • De Prada, Gloria
  • Napoleone, Laura
  • Graupera, Isabel
  • Pose, Elisa
  • Juanola, Adrià
  • Borruel, Natalia
  • Berland, Magali
  • Toapanta, David
  • Casellas, Francesc
  • Guarner, Francisco
  • Doré, Jöel
  • Solà, Elsa
  • Ehrlich, Stanislav Dusko
  • Ginès, Pere
Cirrhosis is associated with changes in gut microbiome composition. Although acute-on-chronic liver failure (ACLF) is the most severe clinical stage of cirrhosis, there is lack of information about gut microbiome alterations in ACLF using quantitative metagenomics. We investigated the gut microbiome in patients with cirrhosis encompassing the whole spectrum of disease (compensated, acutely decompensated without ACLF, and ACLF). A group of healthy subjects was used as control subjects., Stool samples were collected prospectively in 182 patients with cirrhosis. DNA library construction and sequencing were performed using the Ion Proton Sequencer (ThermoFisher Scientific, Waltham, MA). Microbial genes were grouped into clusters, denoted as metagenomic species., Cirrhosis was associated with a remarkable reduction in gene and metagenomic species richness compared with healthy subjects. This loss of richness correlated with disease stages and was particularly marked in patients with ACLF and persisted after adjustment for antibiotic therapy. ACLF was associated with a significant increase of Enterococcus and Peptostreptococcus sp and a reduction of some autochthonous bacteria. Gut microbiome alterations correlated with model for end-stage liver disease and Child-Pugh scores and organ failure and was associated with some complications, particularly hepatic encephalopathy and infections. Interestingly, gut microbiome predicted 3-month survival with good stable predictors. Functional analysis showed that patients with cirrhosis had enriched pathways related to ethanol production, γ-aminobutyric acid metabolism, and endotoxin biosynthesis, among others., Cirrhosis is characterized by marked alterations in gut microbiome that parallel disease stages with maximal changes in ACLF. Altered gut microbiome was associated with complications of cirrhosis and survival. Gut microbiome may contribute to disease progression and poor prognosis. These results should be confirmed in future studies., Sponsored in part by the Instituto de Salud Carlos III through the Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016, project reference PI 12/00330 and PI 16/00043. This grant was co-funded by the European Regional Development Fund (FEDER). This study has been supported in part by an EU Horizon 20/20 Programme (Grant/Award Number H2020-SC1-2016-RTD), LIVERHOPE (Grant/Award Number 731875), and in part by Metagenopolis Grant ANR-11-DPBS-0001 (to Stanislav Dusko Ehrlich). Pere Ginès is a recipient of an ICREA Academia Award.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The role of macrophage-inducible C-type lectin in different stages of chronic liver disease

  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Ortiz, Cristina
  • Torres, Sandra
  • Brol, Max J.
  • Tyc, Olaf
  • Gu, Wenyi
  • Grimm, Christian
  • Zeuzem, Stefan
  • Plamper, Andreas
  • Pfeifer, Philipp
  • Zimmer, Sebastian
  • Welsch, Christoph
  • Schaefer, Liliana
  • Rheinwalt, Karl P.
  • Clària i Enrich, Joan
  • Arroyo, Vicente
  • Trebicka, Jonel
  • Klein, Sabine
The macrophage-inducible C-type lectin (mincle) is part of the innate immune system and acts as a pattern recognition receptor for pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPs). Ligand binding induces mincle activation which consequently interacts with the signaling adapter Fc receptor, SYK, and NF-kappa-B. There is also evidence that mincle expressed on macrophages promotes intestinal barrier integrity. However, little is known about the role of mincle in hepatic fibrosis, especially in more advanced disease stages. Mincle expression was measured in human liver samples from cirrhotic patients and donors collected at liver transplantation and in patients undergoing bariatric surgery. Human results were confirmed in rodent models of cirrhosis and acute-on-chronic liver failure (ACLF). In these models, the role of mincle was investigated in liver samples as well as in peripheral blood monocytes (PBMC), tissues from the kidney, spleen, small intestine, and heart. Additionally, mincle activation was stimulated in experimental non-alcoholic steatohepatitis (NASH) by treatment with mincle agonist trehalose-6,6-dibehenate (TDB). In human NASH, mincle is upregulated with increased collagen production. In ApoE deficient mice fed high-fat western diet (NASH model), mincle activation significantly increases hepatic collagen production. In human cirrhosis, mincle expression is also significantly upregulated. Furthermore, mincle expression is associated with the stage of chronic liver disease. This could be confirmed in rat models of cirrhosis and ACLF. ACLF was induced by LPS injection in cirrhotic rats. While mincle expression and downstream signaling via FC receptor gamma, SYK, and NF-kappa-B are upregulated in the liver, they are downregulated in PBMCs of these rats. Although mincle expressed on macrophages might be beneficial for intestinal barrier integrity, it seems to contribute to inflammation and fibrosis once the intestinal barrier becomes leaky in advanced stages of chronic liver disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Use of Rifaximin in Patients With Cirrhosis

  • Caraceni, Paolo|||0000-0002-1439-056X
  • Vargas Blasco, Víctor|||0000-0002-7190-6948
  • Solà, Elsa|||0000-0001-6897-2760
  • Alessandria, Carlo|||0000-0001-5468-694X
  • de Wit, Koos|||0000-0001-8472-8549
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Angeli, Paolo|||0000-0002-1913-0716
  • Mookerjee, Rajeshwar P.
  • Durand, François
  • Pose, Elisa|||0000-0002-0224-7686
  • Krag, Aleksander|||0000-0002-9598-4932
  • Bajaj, Jasmohan S.|||0000-0003-4928-3681
  • Beuers, Ulrich
  • Ginès, Pere|||0000-0003-4657-4504
Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad-spectrum antibacterial activity covering both gram-positive and gram-negative organisms. Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been proven by large randomized clinical trials. In the last decade, experimental and clinical evidence suggest that rifaximin could have other beneficial effects on the course of cirrhosis by modulating the gut microbiome and affecting the gut-liver axis, which in turn can interfere with major events of the pathophysiological cascade underlying decompensated cirrhosis, such as systemic inflammatory syndrome, portal hypertension, and bacterial infections. However, the use of rifaximin for prevention or treatment of other complications, including spontaneous bacterial peritonitis or other bacterial infections, is not accepted because evidence by clinical trials is still very weak. The present review deals in the first part with the potential impact of rifaximin on pathogenic mechanisms in liver diseases, whereas in the second part, its clinical effects are critically discussed. It clearly emerges that, because of its potential activity on multiple pathogenic events, the efficacy of rifaximin in the prevention or management of complications other than HE deserves to be investigated extensively. The results of double-blinded, adequately powered randomized clinical trials assessing the effect of rifaximin, alone or in combination with other drugs, on hard clinical endpoints, such as decompensation of cirrhosis, acute-on-chronic liver failure, and mortality, are therefore eagerly awaited.